Compare Marriott International Inc (MAR) vs Organon & Co. Common Stock (OGN) Price & Performance

Marriott International (MAR) trades at $371.82, up 0.68% today, near its resistance at $372. The stock shows bullish technical signals with strong moving averages, though the RSI indicates mild overbought conditions. Fundamentally, revenue grew to $26.19B in 2025 with a net income margin of 9.62%, but the P/E of 38.46 and P/B of 443.63 reflect premium valuation. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a quarterly dividend of $0.73 per share.

The outlook for MAR is positive, supported by robust travel demand and strategic initiatives like new technology partnerships. However, risks include high debt levels, with debt-to-asset ratio rising to 55.17% in 2024, and sensitivity to economic cycles. Analysts maintain a consensus price target of $388.93, suggesting moderate upside, but investors should weigh valuation concerns against growth prospects in the hospitality sector.

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.